Experic – a contract development and manufacturing organization (CDMO) and clinical supply services company serving the biopharmaceutical industry – recently announced the successful completion of a Series B extension round of financing. And the additional funding round is earmarked to support the company’s double-digit organic growth and strategic investments in key operational assets.
This funding round will be allocated towards additional investments in the company’s previously announced analytical laboratory and spray drying capabilities, which are critical to enhancing Experic’s manufacturing capabilities.
The strategic investments facilitated by this funding round is expected to bolster Experic’s presence in the biopharmaceutical industry by expanding its service offerings and capabilities.
Experic supports every phase of a product’s life cycle ranging from conception to clinical and commercial scale, across various dosing and packaging formats, including tablets, pellets, capsules, and low dose dry powder inhalation. From the company’s state-of-the-art, Class A cGMP facility, they manage global delivery of the highest quality products, even for expedited projects, while providing unparalleled knowledge, expertise, and customer service.
KEY QUOTE:
“The additional funding from seasoned life science investors in this round will enable us to expand technical capabilities and accelerate growth. This reflects the continued confidence in Experic’s business model, scientific expertise, and the client service we deliver daily.”
- David Wood, CEO and chairman of Experic
